title: Efficacy and safety of emerging immunotherapies in psoriasis.
abstract: Psoriasis is a common chronic inflammatory disease of the skin. Current biologic therapies are highly effective in the treatment of psoriasis, transforming the lives of patients with this significantly disabling disease. Advances in the understanding of the immunological pathogenesis of psoriasis have led to the development of new biologic therapies, targeting specific inflammatory cytokines upregulated in psoriasis. These include the IL-17 antagonists, secukinumab, brodalumab and ixekizumab; the IL-23 antagonists, guselkumab and tildrakizumab; and the oral small molecule therapies, tofacitinib and apremilast. Here, we review evidence for the efficacy and safety of these novel psoriasis therapies, providing clinicians with an overview of the next era in immunotherapy for psoriasis.
authors.affiliation: The Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK.
authors.forename: Zenas Z N
authors.initials: ZZ
authors.lastname: Yiu
authors.forename: Richard B
authors.initials: RB
authors.lastname: Warren
mesh_terms: D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D020381:Interleukin-17 / Q000037:antagonists & inhibitors / Q000276:immunology; D053759:Interleukin-23 / Q000037:antagonists & inhibitors / Q000276:immunology; D011565:Psoriasis / Q000188:drug therapy / Q000276:immunology / Q000473:pathology; D012867:Skin / Q000276:immunology / Q000473:pathology
chemical_list: D000911:Antibodies, Monoclonal; D020381:Interleukin-17; D053759:Interleukin-23
keywords: apremilast; biologics; brodalumab; guselkumab; ixekizumab; psoriasis; safety; secukinumab; tildrakizumab; tofacitinib